Short answer
Absci Corp (ABSI) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $304,000 (down 19.6% year over year) with net income of −$33M.
Q3 2026 key financials · XBRL
- Revenue
- $304,000
- −19.6% YoY · −4.4% QoQ
- Net income
- −$33M
- −16.0% YoY · −0.3% QoQ
- Operating margin
- -11511.2%
- EPS (diluted)
- −$0.20
- +0.0% YoY · +4.8% QoQ
Source: XBRL data from the Absci Corp (ABSI) Q3 2026 10-Q on SEC EDGAR. USD.
Absci Corp Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0.3M, down 20% YoY from $0.4M, reflecting milestone timing and program mix
- Operating loss $35.0M vs $30.2M YoY, with R&D expense $23.6M, up 22%
- Lead program ABS-201: positive interim safety data, half-life at least 65 days
- Cash, equivalents and marketable securities $173.7M; operating cash used $83.3M through nine months
- June offering generated $93.6M; management expects liquidity sufficient for at least 12 months
Risk Factors
- Newly added BIOSECURE Act risk: WuXi AppTec’s June 2026 designation was preliminarily enjoined in August 2026
- Regulatory risk: CMS finalized GLOBE Model for 2027, potentially reducing partner revenue, milestones and royalties
- Clinical risk: ABS-201 Phase 1/2a trial continues dosing MAD cohorts in Australia
- Financial risk: $173.7 million cash, equivalents and marketable securities expected to fund at least 12 months
- Operating risk: No partner has licensed related intellectual property for clinical or commercial use as of November 12, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Absci Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.